A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. [electronic resource]
Producer: 20070913Description: 567-74 p. digitalISSN:- 0007-0920
- Adult
- Aged
- Antigens, Neoplasm -- immunology
- Carcinoma, Renal Cell -- diagnosis
- Disease Progression
- Dose-Response Relationship, Drug
- Drug-Related Side Effects and Adverse Reactions
- Enterotoxins -- administration & dosage
- Female
- Follow-Up Studies
- Humans
- Injections, Intravenous
- Interleukin-2 -- biosynthesis
- Kidney Neoplasms -- diagnosis
- Male
- Membrane Glycoproteins -- administration & dosage
- Middle Aged
- Predictive Value of Tests
- Prognosis
- Recombinant Fusion Proteins -- administration & dosage
- Survival Rate
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.